Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer. Issue 4 (28th December 2020)
- Record Type:
- Journal Article
- Title:
- Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer. Issue 4 (28th December 2020)
- Main Title:
- Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
- Authors:
- Dong, Xiaohan
Chang, Minghui
Song, Xingguo
Ding, Shanshan
Xie, Li
Song, Xianrang - Abstract:
- Abstract: Background: Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). Methods: The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. The differentially expressed miRNAs from 154 primary NSCLC patients and 146 healthy donors were subjected to RNA isolation and verified by quantitative PCR (qPCR). Results: The miRNA microarray analysis revealed that 40 differential miRNAs between NSCLC patients and healthy donors were selected. We found that the plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p levels of patients were significantly higher than those of healthy controls. The receiver operating characteristic curve (ROC) analyses revealed higher area under the ROC curve (AUC) values and higher sensitivity/specificity of carcinoembryonic antigen (CEA) in combination with miR‐1247‐5p, miR‐301b‐3p, or miR‐105‐5p were superior to that of CEA alone. Conclusions: High miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients. Key points: Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC. Abstract : In summary, our results indicate that miR‐1247‐5p, miR‐301b‐3p, and miR‐105‐5p are candidate biomarkers of NSCLC, which performAbstract: Background: Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). Methods: The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. The differentially expressed miRNAs from 154 primary NSCLC patients and 146 healthy donors were subjected to RNA isolation and verified by quantitative PCR (qPCR). Results: The miRNA microarray analysis revealed that 40 differential miRNAs between NSCLC patients and healthy donors were selected. We found that the plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p levels of patients were significantly higher than those of healthy controls. The receiver operating characteristic curve (ROC) analyses revealed higher area under the ROC curve (AUC) values and higher sensitivity/specificity of carcinoembryonic antigen (CEA) in combination with miR‐1247‐5p, miR‐301b‐3p, or miR‐105‐5p were superior to that of CEA alone. Conclusions: High miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients. Key points: Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC. Abstract : In summary, our results indicate that miR‐1247‐5p, miR‐301b‐3p, and miR‐105‐5p are candidate biomarkers of NSCLC, which perform even better when combined with CEA levels. These findings also prompted us to hypothesize that the early dysregulation of miR‐1247‐5p, miR‐301b‐3p, and miR‐105‐5p in the NSCLC disease process, and the requirement of only a small amount of plasma, render miR‐1247‐5p, miR‐301b‐3p, and miR‐105‐5p very suitable as early warning biomarkers for NSCLC. … (more)
- Is Part Of:
- Thoracic cancer. Volume 12:Issue 4(2021)
- Journal:
- Thoracic cancer
- Issue:
- Volume 12:Issue 4(2021)
- Issue Display:
- Volume 12, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 12
- Issue:
- 4
- Issue Sort Value:
- 2021-0012-0004-0000
- Page Start:
- 539
- Page End:
- 548
- Publication Date:
- 2020-12-28
- Subjects:
- Biomarkers -- miR‐105‐5p -- miR‐1247‐5p -- miR‐301b‐3p -- non‐small cell lung cancer
Chest -- Cancer -- Periodicals
Chest -- Cancer -- Treatment -- Periodicals
Chest -- Surgery -- Periodicals
616.99494005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291759-7714;jsessionid=9202029487E02D838DF722140677202D.d04t01 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1759-7714 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.wiley.com/bw/journal.asp?ref=1759-7706&site=1 ↗ - DOI:
- 10.1111/1759-7714.13800 ↗
- Languages:
- English
- ISSNs:
- 1759-7706
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8820.242500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15766.xml